Dusan Bogunovic, PhD
- PROFESSOR | Oncological Sciences
- PROFESSOR | Microbiology
- PROFESSOR | Dermatology
- PROFESSOR | Pediatrics
Research Topics:
Cellular Immunity, Cytokines, Gene Regulation, Gene Therapy, Genetics, Genomics, Human Genetics and Genetic Disorders, Immune Antagonism, Immune Deficiency, Immunological Tolerance, Immunology, Immunosuppression, Infectious Disease, Inflammation, Interferon, Lymphocytes, Viruses and VirologyDusan Bogunovic, Ph.D. is an Associate Professor at the Precision Immunology Institute, Mindich Child Health and Development Institute, Icahn Genomics Institute, and Departments of Oncological Sciences, Microbiology and Pediatrics at the Icahn School of Medicine at Mount Sinai. Dr. Bogunovic also serves as a Director of the Center for Inborn Errors of Immunity at ISMMS.
The Bogunovic lab focuses on the study of human immunogenetics. We aim to improve understanding of the human immune system by studying:
1) Individuals with rare auto-inflammatory syndromes.
2) Individuals with severe clinical presentations of infectious diseases.
3) Developing broad spectrum antiviral therapeutics.
4) Understanding immune system in Down syndrome.
To dissect these phenotypes and develop therapeutics we use genomic, genetic, molecular biology, cellular biology, immunology and clinical tools.
https://labs.icahn.mssm.edu/bogunoviclab/
https://icahn.mssm.edu/research/inborn-errors-of-immunity
Multi-Disciplinary Training Areas
Development Regeneration and Stem Cells [DRS], Microbiology [MIC]Education
PhD, New York University Medical School
Postdoctoral Fellow, The Rockefeller University
-
2019
Hirschl Scholar Award -
2018
Quickfire Challenge Winner -
2017
Lamport Research Award -
2016
Young Investigator Award -
2015
Milstein Award for Young Investigators
Lab Website
https://labs.icahn.mssm.edu/bogunoviclab/
Human Immunogenetics
The Bogunovic lab focuses on the study of human immunogenetics. We aim to improve understanding of the human immune system by studying: 1) Individuals with rare auto-inflammatory syndromes. 2) Individuals with severe clinical presentations of infectious diseases. 3) Developing broad spectrum antiviral therapeutics. 4) Understanding immune system in Down syndrome. To dissect these phenotypes and develop therapeutics we use genomic, genetic, molecular biology, cellular biology, immunology and clinical tools. The hypothesis of the lab is that inter-individual variability in immune responses (in auto-inflammatory syndromes and infections) can also be explained by the immune genetic composition of the host. We aim to illuminate the elusive pathogenesis of these diseases, hoping to lay the foundation for a novel and paradigm-shifting approach to the rational design of both preventative medicine (vaccines and genetic counseling) and treatments beyond currently used antimicrobials.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Bogunovic during 2022 and/or 2023. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Company Founder:
- Lab11 Therapeutics
Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)
- Lab11 Therapeutics Inc
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.